

Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection

Pauline Trémeaux, Tiphaine Lenfant, Faroudy Boufassa, Asma Essat, Adeline Mélard, Marine Gousset, Olivier Delelis, Jean-Paul Viard, Marc Bary, Cecile Goujard, et al.

▶ To cite this version:

Pauline Trémeaux, Tiphaine Lenfant, Faroudy Boufassa, Asma Essat, Adeline Mélard, et al.. Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection. EBioMedicine, 2019, 41, pp.455-464. 10.1016/j.ebiom.2019.02.016 . hal-02348707

HAL Id: hal-02348707 https://hal.science/hal-02348707

Submitted on 22 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Version of Record: https://www.sciencedirect.com/science/article/pii/S235239641930088X Manuscript_90a9938c4a889abd0a086604560e683c

1	Increasing contribution of integrated forms to total HIV DNA in blood
2	during HIV disease progression from primary infection
3	
4	Pauline TRÉMEAUX ^{1,2,3,4*} , Tiphaine LENFANT ^{1*} , Faroudy BOUFASSA ⁵ , Asma ESSAT ^{5,6} ,
5	Adeline MÉLARD ^{1,2,3} , Marine GOUSSET ^{1,2,3} , Olivier DELELIS ⁷ , Jean-Paul VIARD ^{1,2,3,8} ,
6	Marc BARY ⁶ , Cécile GOUJARD ^{5,6} , Christine ROUZIOUX ^{1,9} , Laurence MEYER ^{5,6} ,
7	Véronique AVETTAND-FENOEL ^{1,2,3,9§} , for the ANRS-SEROCO and PRIMO cohorts [^]
8	
9	¹ Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France
10	² INSERM, U1016, Institut Cochin, Paris, France.
11	³ CNRS, UMR8104, Paris, France.
12	⁴ AP-HP, Laboratoire de Virologie, Hôpital Cochin, Paris, France
13	⁵ Université Paris Sud, Université Paris Saclay, INSERM CESP U1018, le Kremlin-Bicêtre,
14	France
15	⁶ AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
16	⁷ Laboratoire de Biologie et Pharmacologie Appliquée, Centre National de la Recherche
17	Scientifique UMR8113, Cachan, France
18	⁸ AP-HP, Centre de diagnostic et thérapeutique, Hôtel-Dieu, Paris, France
19	⁹ AP-HP, Laboratoire de Virologie, CHU Necker-Enfants Malades, Paris, France
20	
21	[*] These authors contributed equally to this work.
22	[§] These authors also contributed equally to this work.
23	[^] Members are listed in the Supplementary Table 1.
24	
25	Corresponding author: Véronique Avettand-Fenoel.

- 26 Laboratoire de Virologie CHU Necker Enfants Malades
- 27 149, rue de Sèvres
- 28 75743 Paris Cedex 15, France
- 29 Phone: (+33) 1 42 19 28 93
- 30 Email: veronique.avettand@aphp.fr

33 Abstract

34 Background: In the current context of research on HIV reservoirs, offering new insights into 35 the persistence of HIV DNA in infected cells, which prevents viral eradication, may aid in 36 identifying cure strategies. This study aimed to describe the establishment of stable integrated 37 forms among total HIV DNA during primary infection (PHI) and their dynamics during the 38 natural history of infection.

39 Methods. Total and integrated HIV DNA were quantified in blood from 74 PHI patients and 40 97 recent seroconverters (<12 months following infection, "progression cohort"). The 41 evolution of both markers over six years were modelled (mixed-effect linear models). Their 42 predictive values for disease progression were studied (Cox models).

Findings. For most patients during PHI, stable integrated forms were a minority among total HIV DNA (median: 12%) and became predominant thereafter (median at AIDS stage: 100%). Both total and integrated HIV DNA increased over a six-year period. Patients from the progression cohort who reached clinical AIDS during follow-up (n=34) exhibited higher total and integrated HIV DNA levels at seroconversion and a higher percentage of integrated forms than did slower progressors (n=63) (median: 100% *vs* 44%). The integrated HIV-DNA load was strongly associated with the risk of developing AIDS (aRR=2.63, *p*=0.002).

50 **Interpretation**. The profile of "rapid" or "slower" progression in the natural history of HIV 51 infection appears to be determined early in the course of HIV infection. The strong 52 predominance of unstable unintegrated forms in PHI may explain the great benefit of this 53 early treatment, which induces a sharp decrease in total HIV DNA.

54 **Funding**. French National Agency for Research on AIDS and Viral Hepatitis.

56 Keywords

- 57 Total HIV DNA; integrated HIV DNA; reservoirs; natural history; primary HIV infection;
- 58 acquired immunodeficiency syndrome; kinetics

60 Introduction

61

62 Combined antiretroviral therapy (cART) has constituted major progress in the treatment of 63 HIV infection and current recommendations are to treat all HIV-infected persons, regardless of the stage of infection. Although cART can efficiently block HIV replication, it cannot 64 completely eliminate the virus from its reservoirs. In particular, infected resting CD4+ T-cells 65 66 containing latent integrated HIV proviruses are refractory to current cART and represent a major hurdle preventing viral eradication ^{1,2}. Understanding the pathogenesis of HIV 67 68 reservoirs is critical for developing and evaluating new therapeutic strategies aimed at viral 69 eradication or functional cure.

70

Integrated HIV DNA is the most stable and functional form of the viral genome. It plays a major role in the pathogenesis of HIV infection and HIV reservoirs, even if it includes both replication-competent and defective genomes ³⁻⁵. Cells containing integrated HIV DNA can produce new infectious virions upon stimulation and activation ^{6,7}. Proviruses persist indefinitely, partly due to the homeostatic proliferation of memory T-cells. In contrast, unintegrated forms, which include linear and episomal HIV DNA with 1- or 2-LTRs, are considered more labile and are surrogate markers of viral replication ^{8,9}.

Total HIV DNA levels in peripheral blood mononuclear cells (PBMCs) have been described during both the natural history of HIV infection and cART ¹⁰. It remains partially unexplained why the decrease in this surrogate marker of the reservoir is greater and faster when treatment is initiated during primary HIV infection (PHI) than during the chronic stage ¹¹⁻¹³. As for integrated HIV DNA, it has been mostly studied in patients on cART ¹³⁻¹⁵. Only a few studies have measured integrated HIV DNA in untreated patients, most of which include fewer than 20 patients ^{14,16-18}. Longitudinal data are even more scarce for both markers: only one study to our knowledge has a follow-up of patients during untreated infection (17 patients during the first year, among which 10 still followed after $2 \cdot 8$ years) ¹⁸. Moreover, some techniques do not allow a comparison between the amounts of total and integrated HIV DNA because of differences in assay standardization ¹⁹ and the long-term dynamics of integrated forms among total HIV DNA have never been described. Besides, all previous results showed a great interindividual variability of total and integrated HIV DNA ^{14,16,17,20,21}, enhancing the need for studies on large cohorts.

92

93 To better understand the establishment and maintenance of the HIV reservoir in the blood, the 94 objectives of this work were i) to describe the contribution of integrated forms to total HIV 95 DNA in untreated patients at different stages from PHI to chronic infection and ii) to evaluate 96 the predictive value of these biomarkers at the time of seroconversion with respect to 97 evolution towards clinical AIDS.

98

99 Materials and Methods

100

101 **Study population**

Patients with a known or estimated date of infection from two ANRS French cohorts were
 selected. The ANRS-PRIMO cohort was approved by the Ile-de-France-3 Ethics Committee

104 (CPP-1157). All patients from both cohorts gave written informed consent.

105 The ongoing ANRS-PRIMO CO6 cohort enrols patients presenting with PHI, as previously 106 described ^{12,22}. All patients are treatment-naïve at inclusion. Patients enrolled between June 107 2015 and April 2016 with available frozen PBMCs samples from the time of their inclusion 108 were selected for this study. In the ANRS-SEROCO CO2 cohort, initiated in 1988, recently diagnosed HIV-infected individuals who were free of AIDS-related diseases at inclusion were enrolled ²³. Follow-up was scheduled every six months until 2009. Patients were selected within this cohort according to the following criteria: enrolment within 12 months following infection, no efficient cART received before inclusion and during the study until 1996, and having at least two frozen PBMCs samples available.

In both cohorts, the infection date was defined as the date of the incomplete Western blot minus one month, or the date of a primary symptomatic infection minus 15 days, or the midpoint between a negative and a positive HIV antibody test.

118

119 Quantification of total HIV DNA and integrated HIV DNA and determination of 120 unintegrated HIV DNA

Total HIV DNA and integrated HIV DNA were quantified in all PBMCs samples. Total DNA
was extracted with the QIAamp DNA Blood Mini Kit (Qiagen, France) according to the
manufacturer's instructions.

124 First, total HIV DNA was quantified by real-time PCR with the Generic HIV DNA CELL kit (Biocentric, France), employing the 8E5 line as the standard ³. Based on a previously reported 125 126 technique²⁴, we developed a nested Alu-LTR PCR assay to quantify the integrated HIV DNA 127 from the same extracts as total HIV DNA, using the HelaR7Neo cell-line as the standard with 128 improved sensitivity and reproducibility (Supplementary Text 1). The quantification threshold varied depending on the number of available cells tested (threshold range [5-97] copies/ 10^6 129 130 PBMCs (0.70-1.97 log₁₀)). The equivalence of HIV DNA copies between HeLaR7Neo and 131 8E5 standards was verified, allowing the determination of the percentage of integrated forms 132 among total HIV DNA. Unintegrated HIV DNA levels were calculated by the difference in 133 the number of copies between total and integrated HIV DNA.

135 Statistical analyses

136 Statistical analyses were performed using Stata software (v14.2, StataCorp, USA) and Prism 137 software (v7, GraphPad, USA). Continuous variables were compared between groups by 138 using Wilcoxon tests and qualitative variables with Fisher's exact tests. Spearman's 139 correlation coefficient was employed to quantify the correlations between continuous 140 variables. Cox models were used to determine the predictive values of HIV DNA levels for 141 clinical AIDS onset. Mixed-effect linear models (MELMs) were employed to estimate 142 changes in total HIV DNA and integrated HIV DNA over time, considering the value at 143 enrolment as time t=0 for each patient. Logarithm₁₀ transformation of HIV RNA and HIV 144 DNA levels was performed to fulfil the model assumptions. Integrated HIV DNA levels were 145 set to half of the threshold when undetectable. To evaluate the robustness of our results, 146 additional analyses were performed, setting the values of undetectable integrated HIV DNA 147 levels to the threshold value, to zero, or to a range of randomized values between 1 and the 148 threshold. All these analyses produced results similar to those obtained when the values of 149 undetectable integrated HIV DNA levels were set to half the threshold value. P values < 0.05150 were considered significant.

151

152 **Results**

153

154 **Patient characteristics**

155 Seventy-four patients who presented during PHI (ANRS-PRIMO cohort 22) were included, 156 with a median [range] estimated time since infection of 1.2 [0.4-2.4] months (Fiebig II-III, 157 n=12; Fiebig IV, n=7; Fiebig V, n=35; Fiebig VI, n=20). Ninety-seven recent seroconverters from the historical ANRS-SEROCO cohort were included (median estimated time between infection and enrolment: $6 \cdot 2 \ [1 \cdot 3 - 11 \cdot 9]$ months) (called later "progression cohort") ²³. The characteristics of the 171 study patients are presented in Table 1. As expected, the PHI patients had higher HIV RNA loads (p < 0.001) (see also Supplementary Figure 1) and lower CD4+ T-cell counts than did those from the progression cohort (p=0.036).

163

Among the progression cohort, the following two groups could be defined regarding subsequent evolution during follow-up: individuals who developed AIDS (rapid progressors, n=34) and those who had not developed AIDS by 1996 (slower progressors, n=63) (Table 1). Notably the follow-up time was significantly longer for the slower progressors group. Hence, AIDS occurrence in rapid progressors was not due to a longer follow-up time.

169

170 Low percentage of integrated forms in PHI, followed by an increase in the first year post171 infection

172 We quantified the amounts of total HIV DNA and integrated HIV DNA in the samples taken 173 at inclusion from all 171 patients. The results were combined to describe the profiles of both 174 markers over the first year following infection (Figure 1a). Loess curves showed a low level 175 of integrated HIV DNA during PHI, which reached higher levels later in the first year 176 following infection, while the level of total HIV DNA was high during PHI and decreased 177 thereafter. Both markers reached a steadier state after 90 days post infection. The percentage 178 of integrated HIV DNA among total HIV DNA was low for patients in the first 90 days after 179 infection (median: 12%), while it became much higher between 3 and 12 months after 180 infection (median: 65%). Accordingly, even though this percentage varied from 0.1 to 100% 181 regardless of the delay between infection and enrolment, the number of patients with a high 182 percentage of integrated HIV DNA increased with increasing time since infection (Figure 1b).

The median total HIV DNA level in PHI patients was $3.59 \log_{10} \text{ copies}/10^6 \text{ PBMCs}$ [range: 184 185 $2 \cdot 11 \cdot 5 \cdot 61 \log_{10}$, which was significantly higher than that in the 97 progression cohort 186 patients $(3 \cdot 22 [2 \cdot 14 - 4 \cdot 30] \log_{10}(p=0.008)$ and $2.96 [1 \cdot 30 - 4.00] \log_{10}(p<0.001)$ for rapid and 187 slower progressors, respectively) (Table 1, Figure 2a). Conversely, the median integrated HIV 188 DNA levels in PHI patients $(2.15 [0.48-4.10] \log_{10} \text{ copies}/10^6 \text{ PBMCs})$ and slower 189 progressors (2.53 [0.30-3.96] \log_{10}) did not significantly differ from each other (p=0.314) but 190 were significantly lower than those in rapid progressors $(3.32 \ [0.60-4.11] \ \log_{10}) \ (p<0.001)$ 191 (Table 1, Figure 2b). Among patients from the progression cohort, both total HIV DNA and 192 integrated HIV DNA levels were significantly higher in rapid progressors than in slower 193 progressors (Table 1). Notably, the median percentage of integrated among total HIV DNA 194 was 100% for rapid progressors, while it was 44% for slower progressors, indicating that 195 integrated HIV DNA already represented the major form of HIV DNA in the rapid 196 progressors group.

197

Overall total HIV DNA levels were significantly correlated with the integrated HIV DNA (Supplementary Figure 2) and plasma HIV RNA levels (Supplementary Figure 3). Interestingly, for PHI patients, the HIV RNA load showed the strongest correlation with the unintegrated HIV DNA level, a marker of ongoing viral replication, while for patients from the progression cohort at the inclusion time (both rapid and slower progressors), the HIV RNA load was more strongly correlated with the integrated HIV DNA level than with the level of unintegrated forms (Supplementary Figure 4-5).

Increase in total HIV DNA and integrated HIV DNA loads during years of untreated infection

208 Among the 97 HIV-infected individuals from the progression cohort, the median time 209 between the first and the last sample was 4.5 years (range: [1.5-7.7]) or 5.8 years [2.9-8.1]210 for rapid progressors or slower progressors, respectively. HIV DNA kinetics were studied 211 based on a total of 340 samples, with a median of four frozen cell samples per patient (range: 212 [2-6]). Total HIV DNA levels significantly increased over time (p < 0.001), showing a +0.627 \log_{10} (+5371 copies/10⁶ PBMCs) increase in rapid progressors and a +0.574 \log_{10} (+2508 213 $copies/10^{6}$ PBMCs) increase in slower progressors over six years (Figure 3a); the increases 214 215 were similar in the two groups (p=0.740). The integrated HIV DNA level also significantly 216 increased over the same six-year period, exhibiting similar increases (p=0.300) in rapid progressors (+0.538 log₁₀ (+5122 copies/ 10^6 PBMCs), p=0.008) and slower progressors 217 $(+0.796 \log_{10} (+1779 \text{ copies}/10^6 \text{ PBMCs}), p<0.001)$ (Figure 3b). Over time, slower 218 219 progressors maintained lower levels of both total HIV DNA and integrated HIV DNA than 220 rapid progressors, while the percentage of integrated forms tended to increase only in slower 221 progressors (p=0.056). During the same six-year period, CD4+ T-cell counts decreased in 222 both groups (p < 0.001), with a steeper decline in rapid progressors than in slower progressors 223 (-427 and -222 CD4+ T-cells/mm³ respectively, p=0.002) (Supplementary Figure 6).

224

Twenty-four patients among the rapid progressors had an available sample from the 12 months before clinical AIDS occurrence or at the AIDS stage. The median total HIV DNA and integrated HIV DNA loads were $3.64 \log_{10} (IQR [3.42-3.98])$ and $3.69 \log_{10} [3.31-3.97]$, respectively. The median percentage of integrated forms was 100% (IQR [82.3-100]).

High predictive value of the integrated HIV DNA load for evolution towards clinicalAIDS

232 Given the observed differences in the viral parameters at inclusion between the rapid and 233 slower progressors groups, we evaluated their predictive value for evolution towards AIDS. 234 The CD4+ T-cell counts at inclusion were similar between the two groups (p=0.124) (Table 235 1) and were not included in the models. Univariate Cox models showed that a one-log increase in the amount of total HIV DNA, integrated HIV DNA, or HIV RNA at the baseline 236 237 was significantly associated with a 2.48- to 3.12-fold increase in the risk of developing AIDS 238 (Table 2). Since the amounts of total HIV DNA and integrated HIV DNA were strongly 239 linked, two separate multivariate Cox models were applied, with adjustment for sex, age and 240 HIV RNA level at enrolment. In the model including total HIV DNA, a higher HIV RNA load 241 was associated with an increased risk of progression to AIDS (adjusted risk ratio for a one-log 242 positive difference (aRR)=2.02, p=0.044) (Table 2). In the second multivariate model, only 243 the integrated HIV DNA load was strongly associated with the risk of progression (aRR=2.63, 244 p=0.002) (Table 2).

245

246 **Discussion**

247

The presence of long-lived infected cells that are not targeted by cART currently prevents viral eradication and cure. Understanding HIV pathogenesis by generating new insights into the dynamics of the HIV DNA components during infection is critical for conceiving of therapeutic strategies targeting these reservoirs.

This was the first large study to quantify both total HIV DNA and integrated HIV DNA, which is the main persistent form of HIV ^{25,26}, in samples collected during PHI, chronic infection, and at various time points until the AIDS stage, which was made possible by two large French cohorts. The ANRS-SEROCO cohort is one of the rare large historical cohorts that included patients in the 1990s who, at that time, remained largely untreated during their follow-up and who had available longitudinal frozen cell samples.

259

260 One of the objectives of this study was to explore the link between the amount of stable 261 proviruses and the risk of HIV disease progression, with the hypothesis that unstable 262 unintegrated forms may have a lesser impact on long-term evolution. From the time of recent 263 seroconversion, the amount of total HIV DNA was higher in rapidly progressing patients than 264 in slower progressors, which agreed with its known predictive value for HIV disease progression ^{10,27}. Here, we report for the first time the predictive value of the amount of 265 266 integrated HIV DNA, which appeared to be even more strongly predictive of the risk of 267 developing clinical AIDS. Integrated HIV DNA is probably mostly responsible for the 268 predictive value of total HIV DNA observed in previous studies, since this stable form of HIV persistence drives the course of infection ^{2,5}. Integrated HIV DNA is indeed the major source 269 270 of the viral replication and the HIV RNA level reflects the proportion of cells containing this 271 HIV stable form. Yet, the pathogenic impact of integrated HIV DNA is not only through the 272 viral replication since its predictive value is independent of the HIV RNA level. Another 273 potential means to drive the pathogenesis could be the production of transcripts and antigens 274 from defective integrated genomes, which do not result in HIV RNA viremia, but contribute to the immune activation, as previously described ²⁸. The concomitant study of total HIV 275 276 DNA and integrated HIV DNA showed that the percentage of integrated forms is highly 277 informative. Indeed, this percentage was already high in rapid progressors at a time point within 12 months from seroconversion and remained high during disease progression,
confirming that early events determine the profile of a "rapid progressor" or "slower
progressor". Total HIV DNA being strongly predictive of progression towards AIDS in PHI ²⁹,
the few PHI patients with a high proportion of integrated forms might be at a particularly high
risk of becoming rapid progressors.

283 These data are in line with the very low levels of integrated HIV DNA observed in the unique 284 group of elite suppressors compared to patients under efficient cART with similar total HIV DNA levels ³⁰. The low levels of integrated HIV DNA may be the consequence of more 285 286 efficient specific cytotoxic T-lymphocyte (CTL) responses. CTLs could have preferentially 287 destroyed cells harbouring integrated viral DNA, in which the viral transcription and 288 translation into proteins is more efficient, eventually leading to the maintenance of lower proportions of integrated forms ³¹. Rapid progressors may have less efficient CTL responses 289 290 and therefore maintain higher levels of integrated HIV DNA.

291

292 Studies examining total HIV DNA have shown that the establishment of reservoirs is a very early event in PHI ³². Although integrated HIV DNA is included in total HIV DNA, 293 294 concomitant study of these two markers showed that they exhibit very different kinetics in the 295 first year of infection, where the first three months after infection stand apart from the 296 following months and years. Integrated HIV DNA levels were found to be low for most 297 patients during PHI, while total HIV DNA levels were particularly high at that time, which was consistent with previous data showing a peak during this stage 29,32 . We observed a slight 298 299 short decrease in integrated HIV DNA levels after the first weeks of infection (Fiebig III-IV), 300 which is in agreement with the results previously reported for 19 untreated PHI patients from 301 whom samples were collected during earlier stages (17 at Fiebig I-II stages), which showed a 302 peak of integrated HIV DNA in week 2 and a decrease until week 6 after enrolment ¹⁸.

303 Ananworanich's work presented some results describing the evolution of total HIV DNA and integrated HIV DNA for ten patients during 144 weeks ¹⁸. However, only the median results 304 305 were presented for these two biomarkers and the proportions of stable forms among total HIV 306 DNA and their evolution over time were not detailed for the different individuals. Thanks to a 307 far greater number of patients and longer follow-up time, we showed here a more extensive 308 increase of the proportion of integrated forms than in this previous work. With techniques 309 allowing the comparison between the levels of total HIV DNA and integrated HIV DNA, we 310 show the benefit of studying the percentage of integrated forms, their heterogeneity between 311 patients and their impact on the outcome of untreated HIV infection. Although several PHI 312 patients had undetectable integrated HIV DNA levels, the technique used here has a low 313 quantification threshold and we are confident these results reflect truly low levels of 314 integrated forms. The longer follow-up time also allowed us to highlight the progressive 315 increase of total HIV DNA, which was not significant in previous shorter studies.

316

317 Taking all these results into account, we propose a model for the evolution of HIV DNA forms in blood during the natural history of HIV infection (Figure 4a). During PHI, the labile 318 319 linear and episomal HIV DNA forms are particularly abundant and mostly constitute evidence of active replication in recently infected activated cells ¹⁷. This observation might be 320 321 explained by the simultaneous cytokine storm and high immune activation detected at this 322 stage. Later during the first year following infection, while the infection is evolving towards a 323 steady state, integrated HIV DNA becomes the major component of the total HIV DNA in 324 most patients. Both HIV DNA markers continue to increase over the subsequent years of 325 follow-up (Figure 4a). The expansion of HIV reservoirs can be linked to several factors: the 326 infection of new cells due to continuous viral replication, the persistence of long-lived infected cells, and the proliferation of infected cells ³³⁻³⁵. The last two factors might explain 327

the increasing contribution of integrated HIV DNA forms, which are transmitted from amother cell to all daughter cells, while unintegrated forms are diluted during cell division.

At the AIDS stage, integrated forms represented the vast majority of HIV DNA in almost all
patients, which demonstrates that during this profound immunodeficiency, the presence of
stable reservoirs is definitely unaffected by cART.

333

334 The models in Figure 4, depicting the evolution of the different viral forms over time, propose 335 an explanation for why very early treatment is highly beneficial. Such early treatment has 336 been proven to be more effective in reducing total HIV DNA levels and restoring immune functions ^{11,12,36,37}. The rapid and steep initial decline of total HIV DNA (Figure 4b) could be 337 338 explained mainly by the elimination of the labile unintegrated forms. Early cART initiation 339 can also limit the establishment of persistent integrated HIV DNA forms and prevent the 340 progressive increase of blood reservoirs observed in the natural history of the infection. 341 Moreover, previous studies have shown that HIV-infected blood cells during PHI are mostly short-lived T-cells ³⁸, which is an additional factor contributing to reservoir instability during 342 343 this stage. Treating HIV-infected individuals as soon as the PHI stage allows partial 344 preservation of the most long-lived memory T-cells from infection and the maintenance of a predominant contribution of the short-lived ones ³⁶⁻⁴⁰. The slower but continued decrease in 345 total HIV DNA at later times following cART initiation might be explained by the death of 346 these short-lived infected cells ^{11,12}. In contrast, in patients treated during the chronic stage 347 348 (Figure 4c), total HIV DNA decreases only shortly after cART initiation, due to the elimination of infected activated cells⁴¹. Integrated HIV DNA, which is highly predominant 349 350 in latently infected cells, persists at high levels thereafter. Long-lived highly proliferative 351 central-memory T-cells have been shown to be the main contributors to HIV blood reservoirs 352 during the chronic stage and in patients treated since the chronic stage, contributing to more

stable reservoirs ^{35,40}. Taken together, these results suggest that during PHI, the existing 353 354 reservoirs, which are mainly composed of short-lived cells infected with unstable viral forms, 355 are easily eliminated through the early initiation of cART. In contrast, in the chronic phase, 356 the blood reservoirs are mainly composed of stable proviruses in long-lived quiescent cells 357 and are unaffected by cART. This could explain the greater impact of treatment when 358 initiated during PHI compared to the chronic phase, which is an additional reason for 359 recommending the treatment of all HIV-infected individuals, including the initiation of 360 treatment as soon as possible in those diagnosed during PHI.

361

362 We acknowledge that in the present study we quantified total and integrated HIV DNA on 363 PBMC and not CD4+ T cells. Nevertheless, in a previous study on patients from the same 364 ANRS-SEROCO cohort, we showed a high correlation of total HIV DNA levels expressed either by copies/ 10^6 PBMC, or copies/ 10^6 CD4+ T-cells or copies/mL of whole blood ⁴². The 365 366 predictive value level on disease progression was similar whatever the expression of the total 367 HIV DNA load. Besides, we only investigated blood reservoirs. Despite the continuous 368 circulation of lymphocytes between the blood and tissues, the dynamics of integrated HIV 369 DNA and total HIV DNA in infected CD4+ T-cell subsets and their relative contributions 370 could differ in lymphoid tissues because of different inflammation and cellular activation 371 levels, which should therefore also be explored.

- 372
- 373

In conclusion, we used two large cohorts of untreated HIV-infected individuals to describe the
evolution of total and integrated HIV DNA loads and their association with disease evolution.
We showed that integrated forms constitute a minority of the HIV DNA present during PHI
and progressively become predominant over time. However, patients with high levels of

378 integrated HIV DNA shortly after infection are at a higher risk of rapid progression towards 379 AIDS, indicating that the rapidity of progression is determined soon after infection. These 380 results highlight that PHI is a key period, and they contribute to the understanding of why 381 cART initiation during this time is most effective in decreasing the HIV DNA burden, thereby 382 protecting immune cells from infection. Concomitant analysis of total HIV DNA and 383 integrated HIV DNA loads contributes to the understanding of HIV persistence and 384 pathogenesis. Studying both markers may help to identify HIV-infected individuals who will 385 be the best candidates for new therapeutic strategies targeting HIV, including cure and/or 386 remission strategies.

387

389 Acknowledgements

This work is dedicated to the memory of Jean-Florian Mettetal, Denis Bucquet, and
Christiane Deveau. We thank all the patients and clinicians who participated in this study,
Laurent Tran and Anne Persoz for data management and the laboratory technicians (EA 7327,
Université Paris Descartes) for their technical assistance. We thank Michaela Müller-Trutwin
and Asier Sáez-Cirión for helpful discussions.

395

396 **Declaration of interests**

397 VAF reports grants from ANRS, during the conduct of the study; other from Janssen, other
398 from ViiV, outside of the submitted work. LM reports grants from ANRS, during the conduct
399 of the study. Other authors have nothing to disclose.

400

401 **Funding sources**

The ANRS-PRIMO and SEROCO cohorts are sponsored by the ANRS (French National Agency for Research on AIDS and Viral Hepatitis). This work was funded by the ANRS. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing the report, or decision to submit for publication.

406

407 Authors' contributions

VAF, CR, LM, and FB designed the study. PT, TL, FB, CR, LM, and VAF interpreted the results. PT and TL produced the virological data. FB and AE gathered the data from the cohorts. CG, MB, and JPV included patients and collected the clinical data. PT, TL, FB, CR, LM, and VAF analysed the data. PT, TL, FB, OD, JPV, CG, CR, LM, and VAF participated in drafting and/or revising the manuscript. VAF was responsible for virological analyses. LM

413	was responsible for statistical analyses and models. AM, MG, and OD provided technical
414	support. VAF supervised the study. All authors critically reviewed and approved the
415	manuscript. PT and TL, as well as LM and VAF, contributed equally to this work.
416	

Note

- 418 Abstract: 262 words
- 419 Body of the text: 3934 words

421 **References**

422

423 1. Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R. HIV reservoirs:
424 what, where and how to target them. *Nat Rev Microbiol* 2016; **14**(1): 55-60.

425 2. Murray JM, Zaunders JJ, McBride KL, et al. HIV DNA subspecies persist in both
426 activated and resting memory CD4+ T cells during antiretroviral therapy. *J Virol* 2014; 88(6):
427 3516-26.

Avettand-Fenoel V, Chaix ML, Blanche S, et al. LTR real-time PCR for HIV-1 DNA
quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in
HAART area (ANRS CO 01). *J Med Virol* 2009; **81**(2): 217-23.

431 4. Bruner KM, Murray AJ, Pollack RA, et al. Defective proviruses rapidly accumulate
432 during acute HIV-1 infection. *Nat Med* 2016; **22**(9): 1043-9.

433 5. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in
434 the latent reservoir increase barrier to HIV-1 cure. *Cell* 2013; **155**(3): 540-51.

435 6. Plantin J, Massanella M, Chomont N. Inducible HIV RNA transcription assays to
436 measure HIV persistence: pros and cons of a compromise. *Retrovirology* 2018; **15**(1): 9.

437 7. Descours B, Avettand-Fenoel V, Blanc C, et al. Immune responses driven by
438 protective human leukocyte antigen alleles from long-term nonprogressors are associated with
439 low HIV reservoir in central memory CD4 T cells. *Clin Infect Dis* 2012; **54**(10): 1495-503.

8. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of
episomal human immunodeficiency virus type 1 cDNA. *J Virol* 2005; **79**(8): 5203-10.

442 9. Mexas AM, Graf EH, Pace MJ, et al. Concurrent measures of total and integrated HIV
443 DNA monitor reservoirs and ongoing replication in eradication trials. *AIDS* 2012; 26(18):
444 2295-306.

445 10. Avettand-Fenoel V, Hocqueloux L, Ghosn J, et al. Total HIV-1 DNA, a Marker of
446 Viral Reservoir Dynamics with Clinical Implications. *Clin Microbiol Rev* 2016; **29**(4): 859-80.

Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy
initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and
normal T cell counts. *J Antimicrob Chemother* 2013; 68(5): 1169-78.

Laanani M, Ghosn J, Essat A, et al. Impact of the Timing of Initiation of Antiretroviral
Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA. *Clin Infect Dis* 2015; **60**(11): 1715-21.

453 13. Koelsch KK, Boesecke C, McBride K, et al. Impact of treatment with raltegravir
454 during primary or chronic HIV infection on RNA decay characteristics and the HIV viral
455 reservoir. *AIDS* 2011; 25(17): 2069-78.

- 456 14. Murray JM, McBride K, Boesecke C, et al. Integrated HIV DNA accumulates prior to
 457 treatment while episomal HIV DNA records ongoing transmission afterwards. *AIDS* 2012;
 458 26(5): 543-50.
- 459 15. Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M,
 460 Vandekerckhove L. Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. *PLoS*461 *Pathog* 2016; **12**(3): e1005472.
- 462 16. Pinzone MR, Graf E, Lynch L, et al. Monitoring Integration over Time Supports a
 463 Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir
 464 Size. *J Virol* 2016; **90**(23): 10436-45.
- 465 17. Zhu W, Jiao Y, Lei R, et al. Rapid turnover of 2-LTR HIV-1 DNA during early stage
 466 of highly active antiretroviral therapy. *PLoS One* 2011; 6(6): e21081.
- 467 18. Ananworanich J, Chomont N, Eller LA, et al. HIV DNA Set Point is Rapidly
 468 Established in Acute HIV Infection and Dramatically Reduced by Early ART. *EBioMedicine*469 2016; **11**: 68-72.
- 470 19. Eriksson S, Graf E, Dahl V, et al. Comparative analysis of measures of viral reservoirs
 471 in HIV-1 eradication studies. *PLoS Pathog* 2013; 9(2): e1003174.
- 472 20. Cortes FH, Passaes CP, Bello G, et al. HIV controllers with different viral load cutoff
 473 levels have distinct virologic and immunologic profiles. *J Acquir Immune Defic Syndr* 2015;
 474 68(4): 377-85.
- 475 21. Vandergeeten C, Fromentin R, Merlini E, et al. Cross-clade Ultrasensitive PCR-based
 476 Assays to Measure HIV Persistence in Large Cohort Studies. *J Virol* 2014.
- 477 22. Ghosn J, Deveau C, Chaix ML, et al. Despite being highly diverse, immunovirological
 478 status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross479 sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J
 480 Antimicrob Chemother 2010; 65(4): 741-8.
- 481 23. Hubert JB, Burgard M, Dussaix E, et al. Natural history of serum HIV-1 RNA levels
 482 in 330 patients with a known date of infection. The SEROCO Study Group. *Aids* 2000; 14(2):
 483 123-31.
- 484 24. Brussel A, Delelis O, Sonigo P. Alu-LTR real-time nested PCR assay for quantifying
 485 integrated HIV-1 DNA. *Methods Mol Biol* 2005; **304**: 139-54.
- 486 25. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH. A sensitive,
 487 quantitative assay for human immunodeficiency virus type 1 integration. *J Virol* 2002;
 488 76(21): 10942-50.
- 489 26. Pinzone MR, Di Rosa M, Cacopardo B, Nunnari G. HIV RNA suppression and
 490 immune restoration: can we do better? *Clin Dev Immunol* 2012; **2012**: 515962.
- 491 27. Rouzioux C, Hubert JB, Burgard M, et al. Early Levels of HIV-1 DNA in Peripheral
- 492 Blood Mononuclear Cells Are Predictive of Disease Progression Independently of HIV-1
- 493 RNA Levels and CD4+ T Cell Counts. *J Infect Dis* 2005; **192**(1): 46-55. Epub 2005 May 31.

- 494 28. Imamichi H, Dewar RL, Adelsberger JW, et al. Defective HIV-1 proviruses produce 495 novel protein-coding RNA species in HIV-infected patients on combination antiretroviral 496 therapy. Proc Natl Acad Sci U S A 2016; 113(31): 8783-8.
- 497 29. Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are 498 independent predictors of disease progression after primary HIV type 1 infection in untreated 499 patients. Clin Infect Dis 2006; 42(5): 709-15.
- 500 Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated 30. HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and 501 502 off HAART. PLoS Pathog 2011; 7(2): e1001300.
- 503 31. Pasternak AO, Lukashov VV, Berkhout B. Cell-associated HIV RNA: a dynamic 504 biomarker of viral persistence. *Retrovirology* 2013; 10: 41.
- 505 32. Ananworanich J, Sacdalan CP, Pinyakorn S, et al. Virological and immunological 506 characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad 507 2016; 2: 43-8.
- 508 33. Bacchus-Souffan C FM, Abdel-Mohsen M, Hoh R, Ahn H, Hecht F, Martin J, Deeks
- 509 S, Liegler T, Hunt M, Hellerstein M, McCune JM. Early initiation of long-term ART may
- 510 favor interventions to eradicate HIV: analysis of cell turnover and persistent HIV reservoirrs
- 511 in distinct CD4+ T cells in suppressed HIV disease. 9th International AIDS Society 512
- Conference. Paris, France; 2017.
- 513 Pasternak AO, Jurriaans S, Bakker M, Berkhout B, Lukashov VV. Steady increase in 34. 514 cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable 515 plasma viremia. AIDS 2010; 24(11): 1641-9.
- 516 35. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven 517 by T cell survival and homeostatic proliferation. Nat Med 2009; 15(8): 893-900.
- 518 36. Li JZ, Gandhi RT. The sooner, the better: more evidence that early antiretroviral 519 therapy lowers viral reservoirs in HIV-infected infants. J Infect Dis 2014; 210(10): 1519-22.
- 520 Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART Intervention 37. 521 Restricts the Seeding of the HIV Reservoir in Long-lived Central Memory CD4 T Cells. 522 CROI 2013; Abst. 47.
- 523 Cheret A, Bacchus-Souffan C, Avettand-Fenoel V, et al. Combined ART started 38. 524 during acute HIV infection protects central memory CD4+ T cells and can induce remission. J 525 Antimicrob Chemother 2015; 70(7): 2108-20.
- 526 39. Bacchus C, Cheret A, Avettand-Fenoel V, et al. A single HIV-1 cluster and a skewed 527 immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within 528 one month post-infection. PLoS One 2013; 8(5): e64219.
- 529 40. Gantner P, Barnig C, Partisani M, et al. Distribution and reduction magnitude of HIV-530 DNA burden in CD4+ T cell subsets depend on art initiation timing. AIDS 2018; 32(7): 921-6.
- 531 41. Murray JM, Zaunders J, Emery S, et al. HIV dynamics linked to memory CD4+ T cell 532 homeostasis. PLoS One 2017; 12(10): e0186101.

- 42. Avettand-Fenoel V, Boufassa F, Galimand J, Meyer L, Rouzioux C, Group ASCS.
 HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. *J Clin Virol* 2008; **42**(4): 399-404.
- 536 43. Cardozo EF, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RM.
- Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves
 that reveals a subset of cells with slow integration. *PLoS Pathog* 2017; 13(7): e1006478.
- Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the
 management of cytomegalovirus in solid organ transplantation. *Transplantation* 2010; **89**(7):
 779-95.
- 542
- 543

544 **Tables and figures**

545

546 **Table 1. Baseline demographic and clinical characteristics of the patients**.

	PHI cohort ^a	Progression cohort ^a	p value ^b	Among the progression cohort			
Characteristics				Rapid progressors	Slower progressors	p value ^b	
n	74	97		34	63		
Male, n (%)	69 (93.2%)	79 (81.4%)	0.040	29 (36.7%)	50 (63.3%)	0.589	
Caucasians, n (%)	61 (82.4%)	95 (97.9%)	<0.001	34 (100.0%)	61 (96.8%)	0.540	
Median age at inclusion (IQR), years	36 (29-45)	30 (26-36)	<0.001	31 (26-37)	30 (26-36)	0.530	
Sexual route of infection, n (%)	72 (97·3%)	88 (90·7%)	0.117	32 (94·1%)	56 (88·9%)	0.487	
Median time between seroconversion and first sample (IQR), months	1.0 (0.8-1.3)	6·2 (4·2-8·5)	<0.001	7·1 (4·4-9·5)	6·0 (4·2-8·3)	0.415	
Median time of follow-up (IQR), years	na	na	na	4.5 (3.5-6.0)	5·8 (4·6-6·3)	0.008	
Median baseline CD4+ cell count (IQR), cells/mm ³	449 (317-613)	531 (390-666)	0.036	481 (343-608)	544 (429-706)	0.124	
Median baseline CD8+ cell count (IQR), cells/mm ³	761 (505-1253)	846 (639-1157)	0.177	927 (632-1157)	832 (650-1144)	0.972	
Median baseline CD4+/CD8+ cell ratio	0.60 (0.37-0.91)	0.57 (0.44-0.87)	0.999	0·52 (0·41-0·77)	0.65 (0.45-0.88)	0.308	
Median plasma HIV RNA load (IQR), log copies/mL	6·20 (5·30-6·98)	4·16 (3·59-4·52)	<0.001	4·37 (3·96-4·67)	3·98 (3·47-4·39)	0.002	
Median total HIV DNA load (IQR), log copies/10 ⁶ PBMCs	3.59 (3.29-4.03)	3·10 (2·73-3·46)	<0.001	3·22 (3·01-3·59)	2·96 (2·63-3·38)	0.008	
Median integrated HIV DNA load (IQR), log copies/10 ⁶ PBMCs	2·15 (0·95-3·16)	2·90 (2·17-3·40)	0.003	3·32 (2·97-3·66)	2.53 (1.52-3.07)	<0.001	

^a PHI refers to patients in the primary HIV infection stage (<3 months since the estimated infection date, ANRS-PRIMO

548 cohort), while patients from the progression cohort were in their first year of infection (ANRS-SEROCO cohort). Rapid and

549 slower progressors groups are defined according to their subsequent progression to clinical AIDS.

550 ^b obtained from Fisher's exact or Wilcoxon rank-sum tests.

551 na: non-applicable


Table 2. Factors associated with the evolution towards clinical AIDS according to baseline levels of total HIV DNA and integrated HIV DNA in univariate and multivariate analyses.

		Univariate analysis			Multivariate analysis including total HIV DNA			Multivariate analysis including integrated HIV DNA		
		RR	95% CI	p value	aRR	95% CI	p value	aRR	95% CI	<i>p</i> value
Sex	male	1			1			1		
	female	0.50	[0.19 - 1.32]	0.161	$1 \cdot 00$	[0.34 - 2.99]	0.995	1.09	[0.38 - 3.14]	0.87
Age at inclusion ^a		1.02	[0.98 - 1.06]	0.249	1.01	[0.97 - 1.05]	0.737	0.70	[0.97 - 1.05]	0.699
log ₁₀ HIV RNA (copies/mL) ^b		2.48	[1.45 - 4.23]	0.001	2.02	[1.02 - 4.00]	0.044	1.42	[0.74 - 2.73]	0.29
log ₁₀ total HIV DNA (copies/10 ⁶ PBMCs) ^b		2.55	$[1 \cdot 24 - 5 \cdot 22]$	0.011	1.47	[0.61 - 3.54]	0.392			
log_{10} integrated HIV DNA (copies/10 ⁶ PBMCs) ^b		3.12	[1.78 - 5.46]	0.000				2.63	[1•41 – 4•91]	0.00


^a for a one-year positive difference; ^b for a one-log positive difference

559 Figure 1. Total HIV DNA and integrated HIV DNA loads in the first year following

- 560 infection
- 561 **a.**



b.




565

567	(a) Distribution with Loess regression of total HIV DNA (filled circles and solid line) and integrated HIV DNA
568	(open circles and dotted line) according to the estimated time since infection (171 patients, one time point per
569	patient at their inclusion in the ANRS-PRIMO cohort (PHI) or the ANRS-SEROCO cohort (progression cohort,
570	divided into rapid and slower progressors)).
571	(b) Repartition of integrated among total HIV DNA percentages according to the time since infection. These
572	percentages were divided into four categories defined by the quartile values obtained for the 171 patients (light
573	blue to purple, with Q1=2%, Q2=28%, Q3=85%)). Patients were classified into five groups defined by the time
574	since infection (in days). The bar chart represents the percentage of patients belonging to each category of
575	integrated/total HIV DNA percentage.
576	

578 Figure 2. Baseline HIV DNA levels during primary infection and recent seroconversion,

579 according to further progression to clinical AIDS.

- 580
- 581 **a.**



583

582


584 Scatter dot plots display (a) total HIV DNA and (b) integrated HIV DNA loads for patients in the primary 585 infection phase (PHI, ANRS-PRIMO cohort, <3 months since the estimated time of infection) and for the rapid 586 progressors and slower progressors groups among the progression cohort (ANRS-SEROCO cohort, <1 year 587 since infection). The bars represent median and interquartile range values.

588

590 Figure 3. Increase in total HIV DNA and integrated HIV DNA over six years of


untreated infection












- 597 (a) Mixed-effect linear models (MELMs) describing the evolution of total HIV DNA over six years for rapid
- 598 progressors (n=34, 111 samples) and slower progressors (n=63, 229 samples).
- (b) MELMs describing the evolution of integrated HIV DNA over six years for rapid progressors (107 samples)
- 600 and slower progressors (207 samples).
- 601 Samples obtained after six years of follow-up were not considered for inclusion in the MELMs to have enough
- 602 results at each time point.
- 603
- 604

605 Figure 4. Proposed models for the dynamics of the different HIV DNA forms in blood

- 606 reservoirs
- **a.**



615 HIV DNA loads are represented in log_{10} copies/10⁶ PBMC. Note the breaks in the time axes.

(a) Model for HIV DNA dynamics during the natural history of infection. During early PHI, total HIV DNA
levels rise rapidly to reach a peak. Integrated HIV DNA shows a concomitant but much lower peak; the majority
of HIV DNA is composed of unintegrated forms at that time ¹⁸. Both total HIV DNA and integrated HIV DNA
display a slight decrease thereafter, before reaching a more stable state. During chronic infection, both HIV
blood biomarkers progressively increase, and the proportion of integrated forms increases.

621 (b, c) Models of HIV DNA dynamics under treatment, depending on the timing of cART initiation. Efficient 622 treatment initiation stops or significantly decreases viral replication and the infection of new cells ⁴³. 623 Unintegrated HIV DNA forms, resulting from viral replication, are eliminated because of their lability or cell 624 death, or they are diluted during cell division, without new production as a result of cART. In contrast, stable 625 integrated HIV DNA can persist for a longer time. Thus, cART initiation at PHI (b), when the integrated HIV 626 DNA level is low, induces a more pronounced and extended decrease of total HIV DNA than cART initiation 627 during the chronic stage, when the predominance of stable integrated forms is already higher (c) ^{11,12}. Efficient 628 treatment initiation stops the evolution of CD4+ T-cell subsets contributions to HIV reservoirs; they remain 629 mainly composed of short-lived cells when cART is initiated during PHI ^{38,40}, while long-lived cells are the 630 major contributor to HIV DNA when cART is initiated during chronic infection ^{35,40}. This difference might 631 explain the continued decrease in total HIV DNA after several years of treatment when cART is initiated early.

633 Supplementary material list

- 634
- 635 Supplementary Table 1. Lists of the SEROCO/HEMOCO Study Group members and
- 636 PRIMO Study Group members.
- 637 **Supplementary Text 1.** Integrated HIV DNA quantification method.
- 638 **Supplementary Figure 1.** Plasma HIV RNA load in the first year following infection.
- 639 Supplementary Figure 2. Correlation between total HIV DNA and integrated HIV DNA
- 640 loads for the 171 patients at inclusion.
- 641 Supplementary Figure 3. Correlation between HIV RNA and total HIV DNA loads for the
- 642 171 patients at inclusion.
- 643 Supplementary Figure 4. Correlation between HIV RNA and integrated HIV DNA loads for
- 644 the 171 patients at inclusion.
- 645 Supplementary Figure 5. Correlation between HIV RNA and unintegrated HIV DNA loads
- 646 for the 171 patients at inclusion.
- 647 Supplementary Figure 6. Dynamics of CD4+ T-cell counts in the natural history of HIV
- 648 infection since recent seroconversion.
- 649 **Supplementary Table 2.** STROBE checklist.